Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Licenses Pharmacogenomic Technology to Millennium

NEW YORK, Jan. 7-Genaissance Pharmaceuticals has licensed its HAP pharmacogenomic platform to Millennium Pharmaceuticals, the company said today.

 

The agreement is a non-exclusive, multi-year agreement under which Genaissance will receive license fees from Millennium. Further financial details were not disclosed.

 

For further information, see the company statement.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.